Recruiting studies: Recurrent Laryngeal Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220 BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734 A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07063212 Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT04754321 Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Phase N/A · 4 location(s) · Vanderbilt University Medical Center · NCT00898638 Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07156227 Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Ch
Phase 2 · 178 location(s) · National Cancer Institute (NCI) · NCT04671667 Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804 Window of Opportunity in Preserving Laryngeal Function Trial
Phase 2 · 1 location(s) · Matthew Spector · NCT07423078 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07419464 FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos,
Phase 2/Phase 3 · 203 location(s) · Bicara Therapeutics · NCT06788990 TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433 Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058 Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i
Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT06980038 Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734 Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT01473784

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.